| Literature DB >> 31125494 |
Youngju Ryu1, Sang Hyun Shin1, Dae Joon Park1, Naru Kim1, Jin Seok Heo1, Dong Wook Choi1, In Woong Han1.
Abstract
BACKGROUND: In 2013, the fistula risk score (FRS) was developed to assess the risk of clinically relevant postoperative pancreatic fistula (CR-POPF). In 2017, the alternative FRS (a-FRS) was proposed. The purpose of this study was to validate the original FRS (o-FRS) and a-FRS for CR-POPF in pancreaticoduodenectomy (PD).Entities:
Keywords: Fistula risk score; Pancreaticoduodenectomy; Postoperative pancreatic fistula; Risk factor; Validation
Mesh:
Year: 2019 PMID: 31125494 PMCID: PMC6771591 DOI: 10.1002/jhbp.638
Source DB: PubMed Journal: J Hepatobiliary Pancreat Sci ISSN: 1868-6974 Impact factor: 7.027
Clinical characteristics of patients included in this study
| Variable |
|
|---|---|
| Age | 62.35 (18‐92) |
| Sex | |
| Male | 1,080 (61.0) |
| Female | 691 (39.0) |
| BMI (kg/m2) | 23.16 (14.4–39.7) |
| Pancreatic fistula | |
| No fistula | 882 (49.8) |
| Biochemical leak | 667 (37.7) |
| ISGPF grade B | 210 (11.9) |
| ISGPF grade C | 12 (0.7) |
| Specific treatment | |
| Use antibiotics | 202 (11.4) |
| Total parenteral nutrition | 57 (3.2) |
| Percutaneous drainage | 99 (5.6) |
BMI body mass index, ISGPF International Study Group of Pancreatic Fistula
Baseline characteristics of fistula risk score factors
| Variable |
|
|---|---|
| Gland texture | |
| Firm | 1,021 (57.7) |
| Soft | 750 (42.4) |
| Pathology | |
| PDAC | 568 (32.1) |
| Other | 1,203 (67.9) |
| Pancreatic duct size (median, mm) | 3.00 (0.2–35) |
| FRS diameter distribution | |
| ≥5 | 456 (25.8) |
| 4 | 210 (11.9) |
| 3 | 439 (24.8) |
| 2 | 445 (25.1) |
| ≤1 | 175 (9.9) |
| EBL (median, ml) | 400 (25–6,000) |
| Intraoperative blood loss (ml) | |
| ≤400 | 1,116 (63.0) |
| 401–700 | 454 (25.6) |
| 701–1,000 | 121 (6.8) |
| ≥1,000 | 80 (4.5) |
EBL volume of intraoperative blood loss, FRS fistula risk score, PDAC pancreatic ductal adenocarcinoma
Ampullary, duodenal, cystic, islet cell
Univariate and multivariate analysis of FRS factor and CR‐POPF
| Risk factor | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Gland texture (soft) | 1.52 | 1.14–2.01 | 0.004 | 1.10 | 0.82–1.48 | 0.534 |
| Pathology (not PDAC) | 3.14 | 2.13–4.64 | <0.001 | 2.72 | 1.83–4.03 | <0.001 |
| Pancreatic duct size, per mm increase | 0.83 | 0.76–0.91 | <0.001 | 0.87 | 0.80–0.94 | 0.001 |
| Estimated volume loss | 1.00 | 1.00–1.00 | 0.827 | |||
| BMI | 1.11 | 1.07–1.16 | <0.001 | 1.09 | 1.05–1.14 | <0.001 |
BMI body mass index, CI confidence interval, OR odds ratio, PDAC pancreatic ductal adenocarcinoma
Figure 1Occurrence of clinically relevant postoperative pancreatic fistula (CR‐POPF) according to the original fistula risk score and alternative fistula risk score. (a) CR‐POPF occurrence according to the original fistula risk score. (b) CR‐POPF occurrence according to the original fistula risk score group. (c) CR‐POPF occurrence according to the alternative fistula risk score group
Figure 2Receiver operating curve (ROC) and the area under the curve (AUC) of the original fistula risk score and alternative fistula risk score. (a) ROC of the original fistula risk score. (b) ROC of the alternative fistula risk score